---
title: "JPEO-CBRND Successfully Fulfills First Year of Annual Procurement Requirement for BioThrax® (Anthrax Vaccine Adsorbed)"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers/jpeo-cbrnd-successfully-fulfills-first-year-of-annual-procurement-requirement-for-biothrax-r-anthrax-vaccine-adsorbed"
date: "2026-07-30T21:15:18+00:00"
language: "en-GB"
---

#  JPEO-CBRND Successfully Fulfills First Year of Annual Procurement Requirement for BioThrax® (Anthrax Vaccine Adsorbed)

 Written by Zoe Rutherford on 05 August 2024.

On July 24, 2024, the Department of Defense (DOD) fulfilled the final Fiscal Year (FY) 2024 delivery of 626,870 doses of the U.S. Food and Drug Administration (FDA)-approved BioThrax® (Anthrax Vaccine Adsorbed), a pre-exposure prophylaxis (PrEP) for anthrax disease. This marks the completion of the first annual delivery – part of a larger procurement contract – which showcases the DOD’s ongoing commitment to vaccine readiness for active-duty service members to support mission needs.

Led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the DOD and the Defense Health Agency, the $235.8 million, 10-year, sole source, indefinite delivery/indefinite quantity (ID/IQ) contract with Emergent Biosolutions, Inc. was awarded on January 09, 2024, for use by all branches of service over the next 10 years.

“This award was the result of an immense effort by the JPEO-CBRND and Army Contracting Command – Edgewood team who worked feverishly for 14 months preparing the contract packet, establishing a Vendor Managed Inventory (VMI) partner, and establishing an order fulfillment mechanism through the U.S. Army Medical Materiel Agency Distribution Operations Center,” said COL Matthew Clark, Joint Project

Manager for the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the JPEO-CBRND. “Fulfillment of this first annual procurement requirement highlights our shared commitment in continuing to provide a layered defense against threats like anthrax to the warfighter.”

The BioThrax® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age, as well as for PrEP in persons at high risk of exposure. It is also approved for post-exposure prophylaxis (PEP) of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.

 [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological)

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" }, { "@type": "ListItem", "position": 3, "name": "JPEO-CBRND Successfully Fulfills First Year of Annual Procurement Requirement for BioThrax® (Anthrax Vaccine Adsorbed)", "item": "https://cbrneworld.com/news/subscribers/jpeo-cbrnd-successfully-fulfills-first-year-of-annual-procurement-requirement-for-biothrax-r-anthrax-vaccine-adsorbed" } ] }
```

```json
{ "@context": "https://schema.org", "@type": "NewsArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://cbrneworld.com/news/subscribers/jpeo-cbrnd-successfully-fulfills-first-year-of-annual-procurement-requirement-for-biothrax-r-anthrax-vaccine-adsorbed" }, "headline": "JPEO-CBRND Successfully Fulfills First Year of Annual Procurement Requirement for BioThrax® (Anthrax Vaccine Adsorbed)", "description": "On July 24, 2024, the Department of Defense (DOD) fulfilled the final Fiscal Year (FY) 2024 delivery of 626,870 doses of the U.S. Food and Drug Administration (FDA)-approved BioThrax® (Anthrax Vaccine Adsorbed), a pre-exposure prophylaxis (PrEP) for anthrax disease. This marks the completion of the first annual delivery – part of a larger procurement contract – which showcases the DOD’s ongoing commitment to vaccine readiness for active-duty service members to support mission needs.Led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the DOD and the Defense Health Agency, the $235.8 million, 10-year, sole source, indefinite delivery/indefinite quantity (ID/IQ) contract with Emergent Biosolutions, Inc. was awarded on January 09, 2024, for use by all branches of service over the next 10 years. “This award was the result of an immense effort by the JPEO-CBRND and Army Contracting Command – Edgewood team who worked feverishly for 14 months preparing the contract packet, establishing a Vendor Managed Inventory (VMI) partner, and establishing an order fulfillment mechanism through the U.S. Army Medical Materiel Agency Distribution Operations Center,” said COL Matthew Clark, Joint Project Manager for the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the JPEO-CBRND. “Fulfillment of this first annual procurement requirement highlights our shared commitment in continuing to provide a layered defense against threats like anthrax to the warfighter.”   The BioThrax® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age, as well as for PrEP in persons at high risk of exposure. It is also approved for post-exposure prophylaxis (PEP) of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs. ", "image": { "@type": "ImageObject", "url": "https://cbrneworld.com/" }, "publisher": { "@type": "Organization", "name": "CBRNe World Magazine", "logo": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/default/Asset%201.png" } }, "author": { "@type": "Person", "name": "Zoe Rutherford", "url": "https://cbrneworld.com/news/subscribers/jpeo-cbrnd-successfully-fulfills-first-year-of-annual-procurement-requirement-for-biothrax-r-anthrax-vaccine-adsorbed" }, "datePublished": "2024-08-05T15:31:32+01:00", "dateCreated": "2024-08-05T15:31:32+01:00", "dateModified": "2024-08-05T15:31:32+01:00" }
```